Menu
image description

Category: Home Page Feature

Investigational CAR T Cell Gets Fast Tracked by U.S. FDA

May 1, 2023 The LRA and our clinical arm Lupus Therapeutics are pleased to share good news from Cabaletta Bio, Inc. that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for CABA-201, a CAR T cell investigational therapy in development to treat systemic lupus erythematosus and lupus nephritis – a common […] Read More

Lupus Research Alliance and its Clinical Research Affiliate Lupus Therapeutics Launch the Lupus Landmark Study to Accelerate Personalized Treatments in Lupus

The Lupus Landmark Study, the largest prospective observational study in lupus, will enroll 3,500 patients throughout North America over five years The Lupus Landmark Study is a key component of the Lupus Nexus, a first-of–its-kind in lupus registry, biorepository and data/knowledge portal NEW YORK, NY. May 23, 2023 – The Lupus Research Alliance and its clinical […] Read More

Lupus Therapeutics Partners with AbbVie on Clinical Trial Recruitment Efforts in SLE Through LuCIN Lupus Clinical Trial Network 

NEW YORK, N.Y., Oct. 24, 2023 – Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, announces a partnership with AbbVie Inc. for the Phase 3 clinical program of upadacitinib (RINVOQ®) in individuals living with systemic lupus erythematosus (SLE). In this partnership, Lupus Therapeutics will assist with study participant recruitment, site activation and […] Read More

Summary Highlights of Important Research Presented at ACR Convergence 2023

November, 2023 At the recent ACR Convergence 2023, the annual meeting of the American College of Rheumatology, important lupus clinical trial data and breakthrough foundational research were presented. Following are highlights of work funded by the Lupus Research Alliance or supported in partnership with industry through our clinical affiliate Lupus Therapeutics. CAR-T Cell Therapy is […] Read More

Study Reported Telitacicept Showed Favorable Effectiveness and Safety for SLE

Dec. 1, 2023 A new paper published in Lupus Science & Medicine on the results of a study in China reported that a potential treatment telitacicept demonstrated favorable effectiveness and safety in patients with active SLE. It also improved effects of lupus on kidneys and the blood. Telitacicept is conditionally approved in China as a […] Read More

Angelica Perez Finds a Simple Way to Make a Huge Difference – You Can Too!

December, 2023 Participating in the LRA’s Lupus Landmark Study was a “no-brainer” says Angelica Perez, a 37-year-old woman living with lupus since she was nine. “I had been taking part in clinical trials for years to potentially improve my own care while helping to advance new treatments overall.” A patient of renowned Los Angeles lupus […] Read More

3 Questions with Dr. Erika Moore

Feb. 22, 2023 The Lupus Research Alliance has funded some of the biggest breakthroughs in lupus research, and we’re pleased to share a new series on the scientists that help make that possible.  The LRA’s Diversity in Lupus Research Awards aim to address underrepresentation of minorities in the scientific research profession.    As part of our […] Read More

LRA-Supported Discovery Highlighted at EULAR

June 19,2019 Partly funded by the Lupus Research Alliance, new results presented at the European Congress of Rheumatology (EULAR) 2019 suggest that some potential cancer treatments may also help patients with lupus.  Dr. Amr Sawalha of the University of Pittsburgh and colleagues have discovered a similarity between immune cells in lupus and some kinds of […] Read More

Advocate for Lupus – Contact Your Legislators

  Advocate for Lupus – Contact Your Legislators! March 21, 2018 The color purple and the word lupus filled the halls of the U.S. Capitol yesterday as over 90 determined advocates visited nearly 100 representatives, senators and staff to share why we need their support for lupus research. And we thank the PA FUND for […] Read More